Items where authors include "Helliwell, P."

Article

Oliver, M., Nuruzzaman, F., Lenert, A. et al. (31 more authors) (2025) Identifying domains for CNO and SAPHO: A scoping review to create domains from existing outcomes by the OMERACT CNO and SAPHO working group. Seminars in Arthritis and Rheumatism, 75. 152862. ISSN 0049-0172

Chapman, L.S., Backhouse, M. orcid.org/0000-0003-0056-8467, Corp, N. et al. (33 more authors) (2025) The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis. Rheumatology, 64 (5). pp. 2355-2368. ISSN 1462-0324

Chapman, L.S., Backhouse, M. orcid.org/0000-0003-0056-8467, Corp, N. et al. (33 more authors) (2025) Executive Summary: The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis. Rheumatology, 64 (5). pp. 2347-2354. ISSN 1462-0324

Winter, E., Dekkers, O., Andreasen, C. et al. (37 more authors) (2025) Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults. Annals of the Rheumatic Diseases, 84 (2). pp. 169-187. ISSN 0003-4967

McHugh, N., Tillett, W., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2024) Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial. Rheumatology. keae374. ISSN 1462-0324

Hen, O., Di Matteo, A., Dubash, S.R. et al. (7 more authors) (2024) High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort. RMD Open, 10 (2). e003841. ISSN 2056-5933

De Lorenzis, E. orcid.org/0000-0001-9819-105X, Kakkar, V., Di Donato, S. et al. (13 more authors) (2024) Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. RMD Open, 10 (1). e003216. ISSN 2056-5933

Coyle, C., Watson, L., Whately-Smith, C. et al. (28 more authors) (2024) How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology. kead679. ISSN 1462-0324

Hailey, L., Bundy, C., Burstow, H. et al. (13 more authors) (2023) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Mease, P. orcid.org/0000-0002-6620-0457, Helliwell, P. orcid.org/0000-0002-4155-9105, Silwinska‐Stanczyk, P. et al. (12 more authors) (2023) Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis & Rheumatology, 75 (8). pp. 1370-1380. ISSN 2326-5191

Hailey, L. orcid.org/0000-0001-5769-8663, Bundy, C., Burstow, H. et al. (13 more authors) (2022) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Madan, J., Ades, T., Barton, P. et al. (9 more authors) (2015) Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2 (2). pp. 113-125. ISSN 2198-6576

Gilworth, G., Emery, P., Barkham, N. et al. (3 more authors) (2009) Reducing work disability in Ankylosing Spondylitis -development of a work instability scale for AS. BMC Musculoskeletal Disorders , 10. ISSN 1471-2474

Firth, J., Hale, C., Helliwell, P. et al. (2 more authors) (2008) The prevalence of foot ulceration in patients with rheumatoid arthritis. Arthritis Care & Research, 59 (2). pp. 200-205.

Conference abstract

Macleod, T., Dubash, S., Hyde, I. et al. (9 more authors) (2024) P51 Plaque psoriasis patients with psoriatic arthritis demonstrate a reduced regulatory capacity for neutrophil elastase compared with plaque psoriasis patients without arthritis. [Conference abstract]

Winter, E., Dekkers, O., Andreasen, C. et al. (37 more authors) (2024) 2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults. [Conference abstract]

Torgutalp, M., Azevedo, V., Baraliakos, X. et al. (39 more authors) (2024) Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS). [Conference abstract]

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. [Conference abstract]

Crowley, A., Siegel, L., Wickersham, P. et al. (6 more authors) (2023) The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study. [Conference abstract]

Helliwell, P., Coates, L., Ransom, M. orcid.org/0000-0003-4359-8287 et al. (5 more authors) (2023) AB1147 The Comparative Performance of Three Screening Questionnaires for Psoriatic Arthritis in a Primary Care Surveillance Program. [Conference abstract]

Mchugh, N., Bojke, L., Coates, L. et al. (7 more authors) (2023) OP0271 Incidence of Psoriatic Arthritis and Prevalence of Undiagnosed Cases in a UK Primary Care Population Followed Prospectively For 2 Years - Results from the TUDOR Randomized Clinical Trial. [Conference abstract]

Brown, S., Coates, L., Collier, H. et al. (6 more authors) (2023) POS0224 Enhanced Surveillance for the Detection of Psoriatic Arthritis in a UK Primary Care Psoriasis Population Versus Usual Care: Results at 24 Months from the the Total Burden of Psoriasis (TUDOR) Randomised Control Trial. [Conference abstract]

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. [Conference abstract]

Watson, L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) Current prescribing practices in psoriatic arthritis - comparison between the UK and Europe. [Conference abstract]

Coyle, C., Watson, L., Brooke, M. et al. (25 more authors) (2023) P174 Psoriatic arthritis patients in the UK have a lower quality of life than patients in mainland Europe - an analysis from the ASSIST study. [Conference abstract]

Watson, L.L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) P179 Shared decision-making in psoriatic arthritis consultations. [Conference abstract]

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. [Conference abstract]

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. [Conference abstract]

Coyle, C., Whately-Smith, C., Brooke, M. et al. (24 more authors) (2022) 1028: How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA? [Conference abstract]

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) 1268: Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. [Conference abstract]

Yazji, S., Helliwell, P., Balanescu, A. et al. (13 more authors) (2022) 1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? [Conference abstract]

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. [Conference abstract]

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. [Conference abstract]

Tillett, W., Coates, L., Sharaf, M. et al. (7 more authors) (2022) 2142: Strong Correlation Between Short- vs Long-form Composite Measures ofPsoriatic Arthritis Disease Activity in a TNFi-IR Population Treated withGuselkumab: Data from the Phase 3b COSMOS Trial. [Conference abstract]

Gladman, D.D., Mease, P.J., Bird, P. et al. (13 more authors) (2022) AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial. [Conference abstract]

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) AB0904 Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. [Conference abstract]

Mulder, M.L.M., Vriezekolk, J.E., Van Hal, T. et al. (7 more authors) (2022) POS0078 Comparing Methotrexate Monotherapy With Methotrexate Plus Leflunomide Combination Therapy In Psoriatic Arthritis: A Randomised, Placebo-Controlled, Double-Blind Clinical Trial (Complete-PsA). [Conference abstract]

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. [Conference abstract]

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. [Conference abstract]

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. [Conference abstract]

Tillett, W., Coates, L., Neuhold, M. et al. (6 more authors) (2022) POS1043 Strong Correlation Between Short- Vs Long-Form Composite Measures Of Psoriatic Arthritis Disease Activity In A TNFi-IR Population Treated With Guselkumab: Data From The Phase 3b Cosmos Trial. [Conference abstract]

Proceedings Paper

Campbell, F., Harrison, S., Golenya, R. et al. (10 more authors) (2024) O12 Community Psoriasis: Phenotype and Comorbidity Assessment (COPPACA): an observational study of the prevalence, phenotype and health burden of psoriasis in the community. In: British Journal of Dermatology. 104th Annual Meeting of the British Association of Dermatologists, 02-04 Jul 2024, Manchester, UK. Oxford University Press , i7-i8.

Preprint

Dand, N. orcid.org/0000-0002-1805-6278, Stuart, P.E., Bowes, J. et al. (82 more authors) (2023) GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. [Preprint]